As much as I'd love this, I'm not sure the math works out as we haven't seen this for the Adderalls, the sibling to Vyvanse. If it were true, Adderall XR alone at a 13% market share would yield 150M+ in annualized rev. That's excluding the higher market share product of Adderall IR and all other products in portfolio.
I think you need to cut it in half again and maybe more so as total market includes significant portion of brand product for Vyvanse.
I think what hits (taking into pharmacy, logistics partners, etc) is about 5% of Adderall market for products recorded as Elite revenue.
Would really love to see otherwise. I'm guessing gross margins on Vyvanse will be much better too, so perhaps my expectations are too conservative, but fierce competition will be picking up too as API becomes more available in the long run.
Let's get that API machine going! I'm not a chemist, but did enjoy couple O Chem classes, would it even be feasibly possible for Elite to build out API mfg and be more vertically integrated? Perhaps this would be the best merger, with our API supplier, capture incremental margin and drive some real financial growrh as we take on our own distribution down road as well.
Market Data 
Markets 
AI
